ÂÜÀòÂÒÂ×

Jonathan Ko is an accomplished professional in the biotherapeutics and pharmaceuticals sector, currently serving as Vice President at Steminent Biotherapeutics since October 2023. With a robust academic background, including a Ph.D. in Pharmaceutical Sciences from Taipei Medical University, Jonathan has held numerous leadership roles such as Special/Executive Assistant to the GM at Medigen Biotechnology Corp., and Vice President at CDIB Capital Group. Jonathan's extensive experience spans board membership at several organizations, including Formosa Pharmaceuticals, Elixiron Immunotherapeutics, and ACT Genomics. Jonathan has a notable history of research and project leadership at ITRI, contributing significantly to drug development, medical devices, and the integration of academic and industry resources for enhanced commercialization efforts.